Trial Profile
Anti-PD-L1 Antibody MEDI4736 in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC). A Multicenter Single-arm Phase II Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Sep 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Cisplatin; Docetaxel
- Indications Adenocarcinoma; Large cell carcinoma; Neuroendocrine carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 09 Aug 2022 Results assessing impact of treatment on the immune system presented at the 2022 World Conference on Lung Cancer
- 20 Jan 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2024.
- 20 Jan 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2024.